Alliancebernstein L.P. Lowers Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Alliancebernstein L.P. reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.7% in the fourth quarter, Holdings Channel reports. The firm owned 3,594,040 shares of the medical research company’s stock after selling 298,602 shares during the period. Alliancebernstein L.P.’s holdings in IQVIA were worth $706,265,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Intech Investment Management LLC bought a new position in IQVIA in the 3rd quarter worth about $223,000. Algert Global LLC bought a new position in shares of IQVIA in the third quarter worth approximately $514,000. Townsquare Capital LLC raised its stake in IQVIA by 5.8% in the third quarter. Townsquare Capital LLC now owns 12,214 shares of the medical research company’s stock valued at $2,894,000 after purchasing an additional 666 shares in the last quarter. CreativeOne Wealth LLC lifted its position in IQVIA by 21.2% during the third quarter. CreativeOne Wealth LLC now owns 3,167 shares of the medical research company’s stock valued at $750,000 after purchasing an additional 553 shares during the last quarter. Finally, Icon Wealth Advisors LLC grew its stake in IQVIA by 88.3% in the 3rd quarter. Icon Wealth Advisors LLC now owns 981 shares of the medical research company’s stock worth $232,000 after buying an additional 460 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 1.2 %

NYSE IQV opened at $177.27 on Monday. The business’s 50-day moving average is $193.15 and its 200 day moving average is $206.05. The stock has a market capitalization of $31.25 billion, a PE ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $176.03 and a 1 year high of $253.84.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on IQV shares. Bank of America dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Citigroup reduced their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.